natgillin/translations-raw huggingface dataset:
A method of making a lyophilised composition for use in a reconstitution solution said method comprising the steps of: mixing WT-1 antigen having an isoelectric point which is lower than the pH of the reconstitution solution and TLR9 agonist, and submitting the resulting formulation to a lyophilisaton cycle. 
Postupak dobivanja liofiliziranog pripravka u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što se sastoji u koracima miješanja željenog antigena i imunostimulacijskog oligonukleotida s pogodnim pomoćnim tvarima, te podvrgavanja dobivene formulacije liofilizacijskom ciklusu.
The aqueous solution is neutralised to pH ~6 by dropwise addition of dil. 
Vodenu otopinu neutralizira se do pH -6 ukapavanjem razrijeđene HCI.
such that the number of projecting lugs is at least twice the number of locking tumblers in said subset, and the number of code recesses in said code pattern of said associated key is also at least twice the number of locking tumblers in said subset, and 
tako daje broj izbočenih stopica barem dvostruki broj čepića za zaključavanje u spomenutom podskupu, te je broj udubljenja u navedenom kodnom uzorku navedenog pripadajućeg ključa također barem dvostruki broj čepića za zaključavanje u spomenutom podskupu, te
to 187.5 g PEG having an average molecular weight of 2500 to 4500 Da; 
(i) 52.5 do 187.5 g PEG koji ima prosječnu molekularnu težinu od 2500 do 4500 Da; i
The new means of production of this pharmaceutical composition has been elaborated for the preparation of infusion solutions of antimicrobial preparations, including mixing of chloride with other components, distinguished by the fact that the powder sodium chloride is mixed with the powder-like colloidal silica at the weight ratio equal to 4.5 or 9: (1-5), respectively, and the obtained mixture is subjected to mechanical treatment by means of impact and abrasive action on the substance to increase the mass fraction of fine-dispersed (less than 5 micron) particles of colloidal silica at least two times. 
Praškasta smjesa za pripremu infuzijskih otopina antimikrobnih pripravaka topiva u sterilnoj vodi za injektiranje, 0,45 %-tna i 0,9 %-tna otopina natrijevog klorida, naznačena time, da praškasta smjesa sadrži praškasti natrijev klorid 1 mehanokemijski aktivirani prah koloidnog silicija 1 natrijevog klorida, pri čemu omjer težine natrijevog klorida i koloidnog silicija iznosi 4,5:1 do 4,5:5 ili 9:1 do 9:5, a mehanokemijski aktivirani prah aktivira se intenzivnim mehaničkim utjecajem 1 abrazivnim djelovanjem te sadrži najmanje 35 % čestica koloidnog silicija veličine < 5 um.
The flexibility of the building is high due to the light construction which makes it easy to rebuild or extend parts of the building. 
Fleksibilnost građevine je velika zbog lagane konstrukcije što ju čini jednostavnom za adaptaciju ili proširivanje dijelova građevine.
Item 33. Upwardly oriented storage according to item 32, further comprising a third exit opposite and below the input opening. 
Prema gore orijentirano skladište prema patentnom zahtjevu 21, koje dodatno sadrži treći izlaz nasuprot i ispod ulaznog otvora.
wherein said antibody is suitable for administering in an effective amount of 0.001-50 mg/kilogram of said cells, tissue, organ or animal; 
(a) pri čemu je spomenuto antitijelo pogodno za primjenu u efektivnoj količini od 0,001-50 mg/kilogram na spomenutim stanicama, tkivu, organu ili životinji;
The process according to claim 1 wherein said compound of formula III is present at 5 moles per mole of the compound of formula (II). 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što je navedeni spoj Formule III prisutan u količini od 5 mol po molu spoja Formule II.
The method according to claim 1, wherein in addition to the liver cells at least one further cell type is present in the microcapsule. 
Postupak za kultiviranje stanice jetre u mediju za kultiviranje naznačen time da se sastoji od kultiviranja mikrokapsule prema bilo kojem zahtjevu od 1 do 13 u pogodnom mediju za kultiviranje.
The smoke inhalation device (100) according to claim 3, wherein the timer (248) is configured to measure the duration of the airstream through the housing (112) each time the sensor (240) is activated by the airstream. 
E-cigareta (100) sukladno patentnom zahtjevu 1, naznačena time što je kućište (112) konfigurirana tako da korisniku omogućuje udisanje prve tvari i pri čemu prva tvar sadrži nikotin.
The recombinant RhCMV or HCMV vector of any one of claims 1-10, or the composition of claim 11, for use in a method of treating a subject at risk of becoming infected with a Paramyxoviridae virus. 
Rekombinantni RhCMV ili HCMV vektor prema bilo kojem od zahtjeva 1-9, ili pripravak prema zahtjevu 10, naznačen time da je za uporabu u postupku liječenja subjekta koji je izložen riziku zaraze sa zaraznom bolesti, pri čemu je zarazna bolest uzrokovana virusom humane imunodeficijencije HIV.
The compound of claim 1, and/or a pharmaceutically acceptable salt thereof, wherein Y is 
Spoj patentnog zahtjeva 1 i/ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju raka.
The device according to one of claims 1 to 9 wherein the variable gap is a largest gap which is an integer multiple of the RBG size and which is available based on the system bandwidth. 
Integrirani krug sukladno jednom od zahtjeva 1 do 14, naznačen time da je razmak najveći od razmaka koji su cjelobrojni višekratnici broja uzastopnih PRB-ova koji tvore RBG i koji su dostupni ovisno o propusnosti sustava.
Pink reaction mixture was vigorously stirred at RT for 20h. 
Ružičasta se reakcijska smjesa snažno miješa 20 h pri sobnoj temperaturi.
Adherent stromal cells of a tissue selected from the group consisting of placenta and adipose tissue for use in treating 
Postupak ekspanzije stanice, naznačen time da sadrži kultiviranje adherentnih stromalnih stanica iz tkiva posteljice kod uvjeta trodimenzionalnog kultiviranja.
The process according to claim 8 wherein after drying the mucilage-free flax sprouts are ground and optionally processed further. 
Postupak prema zahtjevu 8, naznačen time što se nakon sušenja, klice lana bez sadržaja sluzi melju i po izboru dalje obrađuju.
The composition of claim 1, comprising the DNA-targeting RNA, wherein the targeter-RNA and/or the activator-RNA comprises one or more of: a non-natural internucleoside linkage, a nucleic acid mimetic, a modified sugar moiety, and a modified nucleobase. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što RNA koja cilja na DNA sadrži jednu ili više modificiranih nukleobaza, modificiranu okosnicu ili neprirodnu internukleozidnu spojnicu, modificirani šećerni ostatak, zaključanu nukleinsku kiselinu ili peptidnu nukleinsku kiselinu.
The method according to any of the claims 2 to 7, wherein the level of expression of the marker protein or the fragment thereof or the combination of marker proteins or the fragments thereof is detected using a reagent which specifically binds with the marker protein or the fragment thereof or the combination of marker proteins or the fragments thereof. 
Postupak prema bilo kojem zahtjevu 2 do 7, naznačen time, da se razina ekspresije marker-proteina ili njegovog fragmenta ili kombinacije marker-proteina ili njihovih fragmenata otkriva uporabom reagensa koji se specifično veže na marker-protein ili na njegov fragment ili na kombinaciju marker-proteina ili njihovih fragmenata.
The monolithic radiant panel as claimed in claim 15 wherein the modular monolithic radiant panel and the plurality of similar monolithic radiant panels are arranged to form two parallel fluid flow circuits, wherein the direction of fluid flow in one of the fluid flow circuits is opposite to the direction of fluid flow in the other fluid flow circuits. 
Sustav s monolitnim radijativnim panelom u skladu s patentnim zahtjevom 1, naznačen time što svaki od prvog i drugog kruga za protok fluida (402, 404) sadrži više sličnih monolitnih radijativnih panela (100), povezanih u seriju.
A compound according to claim 1, wherein the compound is 4,5-dihydroxy-2-(4-methylbenzyl)isophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 4,5-dihidroksi-2-(4-metilbenziljizoftalonitril.
The method of any claim 1 to 3, wherein the directly measured vitamin D metabolite is selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, 1a,25-dihydroxyvitamin D2, 1a,25-dihydroxyvitamin D3. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što izravno izmjereni metabolit vitamina D se bira iz skupine koju čine 25-hidroksivitamin D2, 25-hidroksivitamin D3, 1a,25-dihidroksivitamin D2 i 1a,25-dihidroksivitamin D3.
The composition of any one of claims 1 to 9, wherein said composition provides a mean Tmax from about 1 to about 6 hours, or from about 2 to about 5.2 hours, after administration. 
Sastav prema bilo kojem od zahtjeva 1 do 9, naznačen time da spomenuti sastav osigurava srednju vrijednost Tax od oko 1 do oko 6 sati ili od oko 2 do oko 5,2 sata nakon primjene.
Step a) converting a carboxy group to a carbamate to form a compound of formula (III) 
Korak a) Pretvorba karboksi skupine spoja formule (III) [image] u karbamat, kako bi se tvorio spoj formule (IV) [image] u kojoj R je kao što je gore definirano;
sulpiride is present in the amount of 0.1-25% w/w; 
(i) sulpirid prisutan u količini od 0,1 do 25% w/w;
wherein the variables R1, R2 and Y have the meaning as defined in claim 1; or 
(IV) gdje varijable R1, R2 1 Y imaju isto značenje kao što je definirano u zahtjevu 1.
The patient is one who has exhibited abnormal biomarkers of liver function after pirfenidone administration as is described above with respect to the methods of the invention for administering pirfenidone to a patient for treating idiopathic pulmonary fibrosis or to a patient who would benefit from pirfenidone administration. In particular, the invention includes pirfenidone for use in treating a patient with idiopathic pulmonary fibrosis or a patient who would benefit from pirfenidone administration, said patient having exhibited a Grade 1 or Grade 2 abnormality in one or more biomarkers of liver function after pirfenidone administration, wherein said patient is administered pirfenidone at doses of 2400 mg/day or 2403 mg/day. 
HR P20110478 T1 PATENTNI ZAHTJEVI Pirfenidon za upotrebu u liječenju pacijenta s idiopatskom pulmonarnom fibrozom (IPF), pri čemu pacijent ima razinu 2 abnormalnosti u jednom ili više biomarkera funkcije jetre poslije davanja pirfenidona, i ima abnormalnu razinu alanin transaminaze (ALT) i/ili aspartat transaminaze (AST) koja je više od 2.5- do 5.0 -puta povećana u usporedbi s gornjom normalnom vrijednošću, poslije davanja pirfenidona, gdje (a) spomenutom pacijentu se daje pirfenidon u dozama od bar 1600 mg/dan ili 1602 mg/dan.
A composition comprising the compound of any one of claims 1-11 or a salt thereof, and a pharmaceutically acceptable carrier. 
Sastav koji obuhvaća spoj prema bilo kojem od zahtjeva 1 do 7 i farmaceutski prihvatljiv nosač.
The method of claim 17, wherein displacing a bromo group is achieved using an agent selected from the group consisting of an a-alkoxy substituted alkyllithium agent, an organomagnesium reagent, a sodium salt of an alkyl derivative, and a sodium salt of an aryl carbamate derivative. 
[image] i opcionalno, pritom se premještanje bromo skupine postiže uporabom sredstva koje je odabrano iz skupine koju čine: a-alkoksi supstituirani alkil-litijev agens, organomagnezijev reagens, natrijeva sol derivata alkila, i natrijeva sol derivata arilkarbamata.
A method according to any one of the preceding claims wherein the compound of formula (II) is: 
postupak sadrži korak reakcije spoja formule (III) sa 2-etilheksanoatnom soli:
the medical composition described in any of the above-mentioned (1) to (7), wherein Z represents a phenyl group, thienyl group, imidazolyl group, thiazolyl group, pyridyl group or pyrimidinyl group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, C1-C4 alkyl group, halogens C1-C4 alkyl group, C1-C4 alkoxyl group and halogeno C1-C4 alkoxyl group, 
Medicinska oftalmološka otopina za uporabu prema bilo kojem od Zahtjeva 1 do 7, gdje Z predstavlja fenil skupinu, tienil skupinu, imidazolil skupinu, tiazolil skupinu, piridil skupinu ili pirimidinil skupinu od kojih svaka može biti supstituirana skupinom/skupinama izabranim iz grupe koju čine atom halogena, C;-Cy alkil skupina, halogeno Ci-C4 alkil skupina, Ci-C4 alkoksil skupina i halogeno C;-Ca alkoksil skupina.
The method of claim 22, wherein the mixing to form the mixture is carried out before the shaping at a temperature of at most 125° C. and for a time not critical for premature vulcanisation, wherein the mixture and/or polymer component(s) are present in a softened state during the mixing. 
Postupak u skladu s patentnim zahtjevom 21, naznačen time što se pravljenje smjese prije oblikovanja provodi na temperaturi i u vremenskom periodu koji nisu kritični za prerano vulkaniziranje, osobito na temperaturi od najviše 125 °C, po mogućnosti u rasponu od 50 °C do najviše 110 °C, i/ili što su smjesa odn. jedna ili više polimernih komponenata prisutne tijekom miješanja u omekšanom stanju.
derived from or associated with thyroid cancer, neuroendocrine cancer, glioblastoma, a female gynecological cancer, any combinations thereof or a metastasis thereof; or 
(i) potječe od ili je povezan s rakom štitnjače, neuroendokrinim rakom, glioblastomom, ženskim ginekološkim rakom, bilo kojom kombinacijom istih ili metestazom istih; ili
A process according to claim 9 wherein the solvent system is methanol, isopropanol, and water in a ratio 1: 6.5: 8 respectively. 
Postupak prema patentnom zahtjevu 9, naznačen time da je sustav otapala metanol, izopropanol i voda u omjeru 1: .
is halogen, OH, or C1-C6 alkyl wherein said C1-C6 alkyl is substituted with 0-6 halogen and wherein up to two non-adjacent CH2 units of said C1-C6 alkyl may be replaced with -O-; 
je halogen, OH ili skupina C1-C6 alkil, pri čemu je navedena skupina C1-C6 alkil supstituirana s 0-6 halogena i pri čemu do dvije CH2 jedinice navedene skupine C1-C6 alkil koje nisu susjedne, mogu biti zamijenjene s-O-;
expression of at least one neural-specific antigen selected from the group consisting of neural-specific tubulin, microtubule associated protein 2, NCAM, and marker for a neurotransmitter after differentiation into a neuronal-like cell; 
- ekspresiju najmanje jednog neuronski-specifičnog antigena koji je izabran iz grupe koja obuhvaća neuronski-specifični tubulin, protein 2 koji se veže za mikrotubule, NCAM, i marker za neurotransmiter;
wherein the amount of non-conjugated antibody in said mixture is in the range of 10-40% by weight; 
O gdje je količina nekonjugiranog protutijela u rasponu od 10-40%, težinski, naznačen time što se sastoji u: a.
After stirring at room temperature for 1 hour, methyl oxalyl chloride (1.29 ml, 14 mmol) is added dropwise to the reaction mixture and stirring continued overnight. 
Nakon miješanja 1 sat pri sobnoj temperaturi u reakcijsku smjesu se doda kap po kap metil oksalil klorid (1,29 ml, 14 mmolova) 1 miješanje se nastavi preko noći.
A preferred point mutation is substitution of amino acid number 1305 based upon alignment with SEQ ID NO: 1. 
Imunogenski polipeptid prema bilo kojem od zahtjeva 1-3, naznačen time da ostatak koji veže cink je amino kiselina broj 1305 zasnovana na svrstavanju sa SEQ ID Br.
The method according to paragraph 6, wherein the L1 signaling information further have PLP PAYLOAD TYPE information which indicates the type of payload data carried by the PLP. 
Metoda u skladu s patentnim zahtjevom 6, pri čemu informacija signaliziranja L1 nadalje ima informaciju vrste podataka PLP polja koja ukazuje vrstu podataka polja koje prenosi pridruženi PLP.
a') protection of the primary amine of 4-aminomethyl-piperidine (2) with ethyl-trifluoroacetate, followed by reductive amination of protected 4-aminomethyl-piperidine with 4-formyl-tetrahydropyran and a borane and by deprotection in basic medium to yield the intermediate diamine (11) 
O wWac sljedećim koracima: a') zaštita primarnog amina 4-aminometil-piperidina (2) OLI N etil-fluoracetatom a zatim reduktivno aminiranje zaštićenog 4-aminometil-piperidina sa 4-formiltetrahidropiranom i boranom te uklanjanje zaštitne skupine u baznom mediju čime nastaje (11),
Aqueous slurry according to one of claims 16 to 19, wherein the ball-shaped surface modified calcium carbonate comprising mineral has a narrow particle size distribution d 98/ d50 of smaller than 2.5, preferably in a range from 1.4 to 2.9. 
Vodena suspenzija prema jednom od zahtjeva 16 do 19, naznačena time da kugličasti površinski modificirani kalcijev karbonat koji sadrži mineral ima usku distribuciju veličine čestica d98/d50 poželjno manju od 3, poželjnije manju od 2.5, poželjno u rasponu od 1.4 do 2.9.
The method of claim 9, wherein the excipient is a solvent, such as sterile water. 
Pripravak u skladu s patentnim zahtjevom 5, naznačen time što je navedena pomoćna tvar otapalo, poput sterile water.
attenuates the ability of a ligand of PD-1 to bind to PD-1; 
(A) smanjuje sposobnost liganda PD-1 da veže na PD-1;
At the age of 10 weeks, before administration (Day 0) and each day for 3 days following administration, animals were subject to the tests described below, as follows: 
U dobi od 10 tjedana, prije primjene (dan 0) 1 svaki dan tijekom 3 dana nakon primjene, životinje su podvrgnute dolje opisanim testovima kako slijedi: Dan -2
Such compositions may in preferred embodiments comprise additional active product ingredients (API), adjuvants, and/or excipients. In a third aspect of the present invention a composition is provided comprising purified recombinant alpha-mannosidase, wherein at least 80% of the alpha-mannosidase is present as a 130 kDa glycoprotein. 
Pripravak dobiven postupkom u skladu s patentnim zahtjevom 14, naznačen time što sadrži pročišćenu rekombinantnu ljudsku lizosomsku a-manozidazu, pročišćenu postupkom u skladu s patentnim zahtjevima 1-8, gdje je najmanje 80% a-manozidaze prisutno u obliku 130 kDa glikoproteina.
The anti-av integrin antibody DI17E6 or a biologically active variant or modification thereof, for use in the treatment of patients suffering from castrate-resistant prostate cancer (CRPC). 
Anti-av integrinsko protutijelo DI17E6 za uporabu prema zahtjevu 4 ili 5, naznačeno time da je smanjenje vrijednosti PSA postignuto nakon 6 mjeseci liječenja.
A method according to any of numbered embodiments 1 to 10, wherein the temperature of the surface of the periphery of the first rotor is at least 100 °C higher than the temperature of the surface of the periphery of the fourth rotor. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što je temperatura površine periferije prvog rotora najmanje 100" C viša od temperature površine periferije četvrtog rotora.
The composition of claim 9 or 10, wherein the one or more modified amino acid residues enhance one or more of in vivo stability, in vivo half-life, uptake/administration, tissue localization or distribution, formation of protein complexes, and/or purification. 
Glikozilirani humani SAP polipeptid u skladu s patentnim zahtjevom 15, naznačen time, da jedan amino kiselinski ostatak ili više aminokiselinskih ostataka povećava in vivo stabilnost, vrijeme in vivo polu-života, unos / primjenu, tkivnu lokalizaciju ili distribuciju, formiranje proteinskih kompleksa i / ili pročišćavanje.
measuring plasma PAA and PAGN levels, calculating a plasma PAA:PAGN ratio, determining whether the PAA prodrug dosage needs to be adjusted based on whether the PAA:PAGN ratio falls within a target range, where a PAA:PAGN ratio below the target range indicates that the dosage potentially needs to be increased and a PAA:PAGN ratio above the target range indicates that the dosage needs to be decreased, and 
određivanje da li doza gliceril tri-[4-fenilbutirata] (HPN-100) treba biti prilagođena na temelju toga da li omjer PAA:PAGN pripada u okvir ciljanog opsega od 1 do 2,5, pri čemu omjer PAA:PAGN ispod ciljanog opsega pokazuje da doza treba biti povećana i omjer PAA:PAGN iznad ciljanog opsega pokazuje da doza treba biti smanjena, i
Preferred embodiments of the invention are as follows: 
Broj objave europskog patenta:
An antibody molecule or pharmaceutical composition for use of any of claims 15-17, wherein the antibody molecule is administered at a dose of about 1 to 30 mg/kg or at a dose of about 1 to 5 mg/kg, optionally wherein the antibody molecule is administered once a week to once every 2, 3, or 4 weeks. 
molekula protutijela, ili farmaceutski pripravak se primjenjuje u dozi od oko 1 do 30 mg/kg ili u dozi od oko 1 do 5 mg/kg; i/ili pri čemu se molekula protutijela, ili farmaceutski pripravak se primjenjuje jednom tjedno do jednom svake 2, 3 ili 4 tjedana.
The resolved fractions are derived from the experiment shown in FIG. 
Razdvojene frakcije dobivene su eksperimentom prikazanim na Slici 1.
The method as in embodiment 13 or 14, wherein the liquid substance is exposed to IR light (23) or hot air. 
Postupak prema zahtjevu 10 ili 11, naznačen time što je tekuća supstanca izložena infracrvenom svijetlu (23) ili toplom zraku.
Furthermore, at least part of a stream of said recirculation may according to another aspect of the present invention be mixed in a ratio with a feed stream of said fluid comprising said homogeneous catalyst and organic material to be converted before entering the catalytic reactor. 
Metoda u skladu s patentnim zahtjevom 58 ili 59, pri čemu je barem dio protoka navedene recirkulacije pomiješan u omjeru s ulaznim protokom navedene tekućine koja obuhvaća navedeni homogeni katalizator i organski materijal za pretvorbu prije ulaska u katalitički reaktor.
The use according to any one of claims 1 to 2, characterized in that the first pH value is pH 5.5 and the second pH value is pH 8.8. 
Uporaba u skladu s jednom od patentnih zahtjeva 1 do 2, naznačena time, da je prva pH vrijednost 5,5, a druga pH vrijednost je 8,8.
Preferably, a composition of this disclosure is formulated for pharmaceutical use (“a pharmaceutical composition”), wherein the carrier is a pharmaceutically acceptable carrier. 
Sastav iz patentnog zahtjeva 5 formuliran za farmaceutsku primjenu i pri čemu je nosač farmaceutski prihvatljivi nosač.
HPLC Retention Time (in minutes) 
[retencije (ulpriprave minutama) ca
It is filtered and the soluble portion is used for the production of cellulases. 
POSTUPAK PROIZVODNJE ENZIMSKOG KOKTELA KORIÅ TENJEM KRUTIH OSTATAKA IZ POSTUPKA ZA BIOKEMIJSKO PRETVARANJE LIGNOCELULOZNIH MATERIJALA
The building block according to claim 1, wherein the diamine and/or polyamine B2) is selected from the following amines, alone or in mixture: 
Armirani građevni blok prema najmanje jednom od prethodnih patentnih zahtjeva, naznačen time što su korišteni amini B2) slijedeći amini, sami ili u smjesama:
The method of claim 3, wherein the effective amount decreases blood, serum or plasma phenylalanine concentration of the subject to a range from below the level of detection to less than about 20 uM. 
Farmaceutski sastav kako je definiran u patentnim zahtjevima 1 do 9 za uporabu u metodi smanjivanja koncentracije fenilalanina u krvi, serumu ili plazmi pacijenta.
The polypeptide according to claim 1, wherein said polypeptide is N-terminally and/or C-terminally modified. The polypeptide according to claim 3, wherein said polypeptide comprises an N-terminal acetyl-, hexanoyl-, decanoyl-, myristoyl-, NH—(CH2—CH2—O)11—CO— or propionyl-residue and/or a C-terminal amide-, NH—(CH2—CH2—O)11—CO-amide-, or one or two amino-hexanoyl groups. 
Polipeptid sukladno patentnom zahtjevu 1 ili 2, naznačen time, da je navedeni polipeptid izborno N-terminalno i/ili C-terminalno modificiran, a prvenstveno sadrži N-terminalni acetil, heksanoil-, dekanoil-, miristoil-, NH-(CH2-CH2-O)11-CO- ili propionil ostatkom i/ili sadrži C-terminalni amid-, NH-(CH2-CH2-O)11-CO-amid-, ili jednu ili dvije amino-heksanoil skupine.